IDEXX Laboratories, Inc. (IDXX) posted third-quarter 2024 earnings per share (EPS) of $2.80, up 10.7% year over year. The figure surpassed the Zacks Consensus Estimate by 4.1%.Comparable constant-currency EPS of $2.79 improved 12% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, IDXX stock fell 3.1% at the pre-market trading today.IDEXX’s Revenues in DetailQuarterly revenues increased 6.6% year over year (up 6% organically) to $975.5 ...

For the quarter ended September 2024, Idexx Laboratories (IDXX) reported revenue of $975.54 million, up 6.6% over the same period last year. EPS came in at $2.80, compared to $2.53 in the year-ago quarter.The reported revenue represents a surprise of -0.41% over the Zacks Consensus Estimate of $979.59 million. With the consensus EPS estimate being $2.69, the EPS surprise was +4.09%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.09%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.87 per share when it actually produced earnings of $2.44, delivering a surprise of -14.98%.Over ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results ▪ Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. ▪ Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth. ▪ Delivers EPS of $2 ...

In its upcoming report, Idexx Laboratories (IDXX) is predicted by Wall Street analysts to post quarterly earnings of $2.69 per share, reflecting an increase of 6.3% compared to the same period last year. Revenues are forecasted to be $979.05 million, representing a year-over-year increase of 6.9%. Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of th ...

IDEXX Laboratories, Inc. (IDXX) is set to release third-quarter 2024 results on Oct. 31, before the opening bell. The company posted adjusted earnings per share (EPS) of $2.44 in the last reported quarter, which missed the Zacks Consensus Estimate by 14.98%. IDEXX Laboratories beat earnings estimates in three of the trailing four quarters and missed in one, the average surprise being 1.51%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. IDXX's Q3 Estimates For the third quarter of 2 ...

It has been about a month since the last earnings report for Idexx Laboratories (IDXX) . Shares have added about 0.9% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Idexx due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. IDEXX Misses Q2 Earnings Estimates, Narro ...

文章核心观点 - 公司IDEXX在2024年第二季度财报中下调了全年有机收入增长预期，主要原因是美国临床访问量减少 公司股票目前仍被高估，未充分反映短期逆风因素，因此维持“卖出”评级，目标价为每股440美元 [1][4][12][24] 公司业绩 - 公司下调2024财年全年有机收入增长预期至6.2% - 7.8%，主要受美国临床访问量减少影响 [1][4][5] - 第二季度伴侣动物集团（CAG）有机收入增长放缓至6.7%，主要受非健康访问诊断频率下降影响 [2][3] - 管理层预计2024财年下半年美国临床访问量疲软将持续，导致全年指引下调 [4][5] 财务表现 - 2024财年全年收入指引下调至38.85亿 - 39.45亿美元，有机增长6.2% - 7.8% [5] - 2024财年CAG诊断业务收入指引下调至5.7% - 7.3%，有机增长6.2% - 7.8% [5] - 2024财年运营利润率预计为28.7% - 29.0%，较之前指引下降130 - 100个基点 [5] - 2024财年每股收益（EPS）预计为10.31 - 10.59美元，同比增长2% - 5% [5] 市场环境 - 美国临床访问量减少主要受宏观经济因素影响，如高利率和疲软的劳动力市场 [10][11] - 消费者因现金流紧张减少非必需品支出，影响公司非健康相关业务 [10] - 高利率持续可能导致临床访问量短期内难以恢复 [6] 产品与创新 - 公司计划在2024年第四季度推出催化剂平台的新测试菜单，扩展到胰腺脂肪酶测试 [7] - 新测试菜单将为兽医提供10分钟内的定量结果，增强催化剂平台的竞争力 [8] - 公司近年来将点对点诊断作为战略重点，拥有大量高端仪器（如催化剂、Procyte和Sedi Vue Dx）的安装机会 [9] - 预计公司将继续推出新产品或增强现有产品组合，以扩大点对点市场，推动诊断业务增长 [9] 长期展望 - 预计2024财年整体收入将增长7%，伴侣动物业务增长7%，水业务和畜禽奶牛业务增长6% [11][12] - 从2025财年开始，预计伴侣动物业务将恢复到每年12%的增长，畜禽奶牛和水业务增长6%，整体收入增长11.4% [13] - 预计公司每年将实现30个基点的利润率扩张，主要来自定价增长、SG&A和R&D的运营杠杆 [13] 估值 - 基于DCF模型，计算得出2024财年目标价为每股440美元 [22] - 风险包括低美国临床访问量持续、宏观经济挑战未缓解等 [24] - 潜在上行风险包括软件和服务业务超预期增长、股市进入熊市时公司可能受到青睐等 [23]

收入增长 - 公司总收入增长6.4%，达到10.036亿美元[204] - 伴侣动物集团(CAG)收入增长6.7%，其中美国市场增长5.2%，国际市场增长10.1%[206] - 水质业务(Water)收入增长9.5%，其中美国市场增长15.3%[207] - 畜牧、家禽和乳品(LPD)业务收入增长2.9%，其中美国市场增长15.7%[208] - 公司总收入增长6.7%，其中有机增长6.8%[260] - 诊断业务经常性收入增长带动总收入增长，受益于全球价格上涨和销量增加[262] - 水业务收入增长9.6%，主要受益于价格上涨和美国及部分国际地区销量增加[257] - 生命科学与诊断业务收入下降1.0%，主要由于中国需求下降，部分被美国和欧洲的价格上涨和销量增长所抵消[258] - 公司CAG诊断业务的经常性收入增长6.7%，主要由于价格上涨和销量增加[272] - IDEXX VetLab耗材收入增长8.0%，主要由于价格上涨和销量增加[273] - 快速检测产品收入增长5.7%，主要由于价格上涨部分抵消了销量下降[274] - 参考实验室诊断和咨询服务收入增长5.9%，主要由于价格上涨和美国及欧洲亚太地区检测量增加[275] - CAG诊断服务和配件收入增长5.1%，主要由于仪器安装基数增加11%[276] - CAG诊断资本-仪器收入增长3.3%，主要由于产品组合有利和高端仪器销量增加部分抵消了价格影响[277] - 兽医软件、服务和诊断成像系统收入增长11.8%，主要由于价格上涨和订阅及支持收入增加，但硬件销售下降[278] 毛利率和费用 - 毛利率提升至61.7%，较上年同期增加1个百分点[214] - 毛利率提高100个基点，主要由于价格上涨抵消了通胀成本影响、软件服务毛利率提高以及业务组合有利变化[232] - 毛利率提升110个基点，主要受益于价格上涨抵消了通胀成本影响、仪器成本下降、软件服务毛利率提升以及业务结构改善[266] - 销售和营销费用增加0.8%，主要由于差旅费用增加[233] - 一般和行政费用增加84.4%，主要由于与正在进行的诉讼事项相关的6150万美元费用以及外部服务成本增加[233] - 研发费用增加21.5%，主要由于项目成本和人员相关成本增加[233] - 销售及营销费用增加1.3%，主要由于差旅费用和人员成本增加[265] - 管理及行政费用增加56.0%，主要由于计提6150万美元的诉讼费用、去年有1600万美元的客户合同解决收益以及外部服务费用增加[267] - 研发费用增加18.6%，主要由于项目成本和人员成本增加[267] 汇率影响 - 外汇变动对收入增长产生0.7%的负面影响，收购对收入增长贡献0.3%[210] - CAG Diagnostics 经常性收入增加主要由于价格上涨和销量增加所致，外汇汇率变动对收入增长产生了0.7%的负面影响[222] - IDEXX VetLab 耗材收入增加主要由于价格上涨和销量增加所致，外汇汇率变动对收入增长产生了1.0%的负面影响[223] - 快速检测试剂收入增加主要由于价格上涨，部分被销量下降所抵消，外汇汇率变动对收入增长产生了0.4%的负面影响[224] - 参考实验室诊断和咨询服务收入增加主要由于美国、欧洲和亚太地区的检测量增加以及价格上涨所致，外汇汇率变动对收入增长产生了0.5%的负面影响[225] - CAG Diagnostics 服务和配件收入增加主要由于仪器安装基数增加11%所致，外汇汇率变动对收入增长产生了1.0%的负面影响[226] - CAG Diagnostics 资本 - 仪器收入增加主要由于产品组合改善和高端仪器销售增加所致，部分被价格折扣所抵消，外汇汇率变动对收入增长产生了1.2%的负面影响[227] - 兽医软件、服务和诊断成像系统收入增加主要由于安装基数扩大带来的经常性收入增加和价格上涨所致，系统和硬件收入下降主要由于新软件销售主要为基于云的销售所致，外汇汇率变动对收入增长产生了0.1%的负面影响，收购增加了4.5%的收入增长[228] 营业利润 - 营业收入增长6.4%，主要由于价格上涨和销量增加[220] - 经营利润下降10.9%，主要受到一次性诉讼费用的影响[215] - 收入下降12.2%至78.82亿美元[297] - 毛利率增加35.4%至45.7%[297] - 销售和营销费用下降39.1%至9.29亿美元[298] - 一般和行政费用增加67.8%至19.77亿美元[298] - 研发费用下降5.7%至4.89亿美元[298] - 营业利润下降2.6%至-7.66亿美元[298] 其他财务指标 - 利息费用下降32.5%至1.6亿美元，利息收入增加至0.78亿美元[302] - 税率为20.9%[303] - 现金及现金等价物为4.016亿美元，其中1.517亿美元为银行存款，2.498亿美元为美国政府货币市场基金[309] - 经营活动产生的现金流入增加6,267.1万美元[314] 其他信息 - 公司

Tuesday, Idexx Laboratories Inc IDXX reported second-quarter adjusted EPS of $3.02, up 15% year-overyear, beating the consensus of $2.88. The company reported sales of $1 billion, an increase of 6% as reported and 7% organically, almost in line with the consensus of $1.01 billion. The revenue growth was driven by Companion Animal Group growth of 6% as reported and 7% organic and Water revenue growth of 9% as reported and 10% organic. Related: Aging Pet Population Is 'Solid Longer-Term Tailwind' For Idexx La ...